Oncology: EMEA Approval Lags

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-10-01-2001, Volume 0, Issue 0

London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.